MY108864A - Peptide-carbohydrate conjugates generating t-cell immunity - Google Patents

Peptide-carbohydrate conjugates generating t-cell immunity

Info

Publication number
MY108864A
MY108864A MYPI93000788A MYPI19930788A MY108864A MY 108864 A MY108864 A MY 108864A MY PI93000788 A MYPI93000788 A MY PI93000788A MY PI19930788 A MYPI19930788 A MY PI19930788A MY 108864 A MY108864 A MY 108864A
Authority
MY
Malaysia
Prior art keywords
carbohydrate
peptide
cell immunity
generating
immunogenic
Prior art date
Application number
MYPI93000788A
Other languages
English (en)
Inventor
Mikael Jondal
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of MY108864A publication Critical patent/MY108864A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI93000788A 1992-04-28 1993-04-28 Peptide-carbohydrate conjugates generating t-cell immunity MY108864A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (1)

Publication Number Publication Date
MY108864A true MY108864A (en) 1996-11-30

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI93000788A MY108864A (en) 1992-04-28 1993-04-28 Peptide-carbohydrate conjugates generating t-cell immunity

Country Status (19)

Country Link
US (2) US5807559A (fr)
EP (1) EP0675733B1 (fr)
JP (1) JPH07506358A (fr)
CN (1) CN1096032A (fr)
AT (1) ATE197903T1 (fr)
AU (1) AU676679B2 (fr)
CA (1) CA2134097A1 (fr)
DE (1) DE69329735T2 (fr)
DK (1) DK0675733T3 (fr)
ES (1) ES2155070T3 (fr)
GR (1) GR3035501T3 (fr)
IL (1) IL105503A (fr)
IS (1) IS4010A (fr)
MA (1) MA22885A1 (fr)
MY (1) MY108864A (fr)
PT (1) PT675733E (fr)
SI (1) SI9300223A (fr)
TN (1) TNSN93045A1 (fr)
WO (1) WO1993021948A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (fr) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Lymphocytes t a cytolyse specifique des glucides
WO1998043677A1 (fr) * 1997-03-27 1998-10-08 Institut Pasteur Conjugue antigenique multiple glucidique et peptidique, vaccin le contenant et son utilisation
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
WO1998046246A1 (fr) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research GLYCOCONJUGUES A LIAISON α-O COMPRENANT DES EPITOPES (2.6)-ST-GROUPES, PROCEDES DE PREPARATION ET UTILISATION DE CES GLYCOCONJUGUES
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
WO1999048515A1 (fr) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Conjugues de glycopeptides a liaison o antigeniques trimeres, procedes de preparation et utilisation de ceux-ci
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
CA2347067C (fr) 1998-03-31 2013-09-17 Geron Corporation Vaccin a base de cellule dendritique contenant de la transcriptase inverse de la telomarase pour le traitement du cancer
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
JP5111705B2 (ja) * 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
KR20050099536A (ko) * 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
WO2005077411A2 (fr) * 2004-02-10 2005-08-25 Innate Pharma Composition et procede pour le traitement de carcinome
CA2607004C (fr) 2005-05-05 2016-01-26 Sensient Flavors Inc. Production de beta-glucanes et de mannanes
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
CA2794196A1 (fr) 2010-03-23 2011-09-29 Intrexon Corporation Vecteurs exprimant des proteines therapeutiques de maniere conditionnelle, cellules hotes comprenant les vecteurs, et utilisations associees
EP2500033A1 (fr) 2011-03-17 2012-09-19 Institut Pasteur Procédé pour la préparation de plusieurs conjugués de carbohydrate de glycopeptide d'antigène
JP2014524796A (ja) 2011-06-28 2014-09-25 イノビオ ファーマシューティカルズ，インコーポレイティド 低侵襲表皮電気穿孔装置
EP2606897A1 (fr) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Procédés et compositions pour le traitement des maladies causées par les virus enveloppés
EP3651795A4 (fr) * 2017-07-12 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Compositions et méthodes pour le traitement de cancers présentant une mutation h3k27m

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (fr) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Stimulation de la reponse immunitaire cellulaire
WO1989006974A2 (fr) * 1988-02-01 1989-08-10 Praxis Biologics, Inc. Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues
AU4030989A (en) * 1988-02-12 1989-09-06 Regents Of The University Of California, The Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (fr) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methodes de production d'anticorps et induction de reponses immunitaires aux gangliosides associes aux tumeurs par immunisation avec des lactones de gangliosides
CA2063271A1 (fr) * 1989-07-14 1991-01-15 Subramonia Pillai Vecteurs de cytokine et d'hormones pour vaccins conjugues
WO1991003494A1 (fr) * 1989-08-28 1991-03-21 Pierce Chemical Company Porteurs cationises pour la production d'immunogenes
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
CN1096032A (zh) 1994-12-07
SI9300223A (en) 1994-03-31
US6033669A (en) 2000-03-07
TNSN93045A1 (fr) 1994-03-17
CA2134097A1 (fr) 1993-11-11
IL105503A0 (en) 1993-08-18
US5807559A (en) 1998-09-15
IS4010A (is) 1993-10-29
AU4274693A (en) 1993-11-29
DE69329735T2 (de) 2001-08-02
DK0675733T3 (da) 2001-05-07
ES2155070T3 (es) 2001-05-01
GR3035501T3 (en) 2001-06-29
IL105503A (en) 1999-05-09
JPH07506358A (ja) 1995-07-13
DE69329735D1 (de) 2001-01-11
WO1993021948A1 (fr) 1993-11-11
ATE197903T1 (de) 2000-12-15
EP0675733B1 (fr) 2000-12-06
MA22885A1 (fr) 1993-12-31
AU676679B2 (en) 1997-03-20
PT675733E (pt) 2001-05-31
EP0675733A1 (fr) 1995-10-11

Similar Documents

Publication Publication Date Title
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
DE69835201D1 (en) Neoglycoproteine
ATE321131T1 (de) Mutierte klasse-i-mhc-moleküle
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
ID28003A (id) Turunan-turunan adamantana
AP9801392A0 (en) Concentrated antibody preparation.
DK0699077T3 (da) Immunogele HIV-komplekser
AU3963889A (en) Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
DE68906366D1 (en) Cd4-polypeptidderivate.
ATE277624T1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
TR199501654A3 (fr)
AU625083B2 (en) Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)- en-20-yn-3-one
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
DK0822808T3 (da) Kompositmateriale med natriumstivelsesglycolat som bærermateriale og produkter deraf
AU3170193A (en) Therapeutic nucleosides
TW332816B (en) Peptide and carbohydrate
AU3445489A (en) Luminide and macroluminide class of pharmaceuticals
JO1766B1 (en) Effective new compounds
HU9600736D0 (en) Novel urethane-containing aminosteroid compounds
IL115740A0 (en) A childproof package for active substance patches and a process for the production thereof
ZA916313B (en) New use of a monoclonal antibody
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
BG98538A (en) Means for anti-hiv therapy
BG100055A (en) Kalfinella sacoidosis sp. novo strain for making preparations for allergological, serological and immunological diagnosis of sarcoidosis, crohn's disease and mediterranean fever